Intellia Therapeutics Advances CRISPR Gene Editing: Lonvo-z Achieves Phase 3 Success for HAE, Targeting Mid-2027 U.S. Launch; Nex-z Phase 3 Enrollment Resumes for ATTR

August 17, 2026

Intellia Therapeutics, Inc. (Press Release) USA

Overview

Intellia Therapeutics reported positive Phase 3 results for lonvo-z in hereditary angioedema (HAE), with a Biologics License Application (BLA) submission to the FDA planned for H2 2026 and a projected U.S. launch in H1 2027. Concurrently, patient enrollment for the Phase 3 trial of nex-z for transthyretin amyloidosis (ATTR) has restarted, aiming for completion by H2 2026. These milestones highlight the company’s progress in bringing its leading in vivo CRISPR gene editing programs closer to commercialization, signifying a critical advancement in the gene therapy landscape.

In Depth

Key Findings

Intellia Therapeutics announced strong results from the Phase 3 HAELO trial of lonvo-z for hereditary angioedema (HAE), exceeding expectations. This success paves the way for a Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) in the second half of 2026, with a planned U.S. launch in the first half of 2027. Additionally, patient enrollment has resumed for the Phase 3 clinical trial of nex-z, targeting transthyretin amyloidosis (ATTR), with an anticipated completion of enrollment in the second half of 2026.

Technical / Clinical Details

Lonvo-z employs an in vivo CRISPR/Cas9 system designed to knock down the kallikrein gene in the liver, which is responsible for HAE. The Phase 3 HAELO trial demonstrated a significant reduction in HAE attack frequency compared to placebo, meeting both primary and secondary endpoints. The safety profile was favorable, with no serious adverse events reported. Nex-z, also a CRISPR-based therapy, targets ATTR, a progressive disease characterized by amyloid deposition in organs such like the heart and nerves. The resumption of its Phase 3 trial enrollment signifies successful resolution of previous regulatory discussions and continued development progress.

Background & Context

For rare genetic conditions like HAE and ATTR, gene editing therapies offer the potential for transformative, long-lasting therapeutic effects, significantly improving patients’ quality of life. The impending BLA submission for lonvo-z underscores the maturing landscape of CRISPR technology, moving from research to tangible clinical applications. This development serves as a crucial benchmark for the broader gene therapy sector. Moreover, ATTR represents a significant unmet medical need, and the advancement of nex-z offers new hope for patients with limited treatment options.

Strategic Significance & Outlook

The FDA submission and subsequent launch of lonvo-z would mark Intellia Therapeutics’ first commercial product, establishing a vital revenue stream and validating its CRISPR platform. Continued clinical development of nex-z further diversifies the company’s pipeline and showcases the versatility of its in vivo gene editing approach. Successful regulatory approvals and market introductions for these therapies are expected to accelerate the adoption of gene editing, driving further research and application across a broader spectrum of genetic diseases. This will undoubtedly catalyze the growth and evolution of the entire gene therapy industry.

Source: https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-second-quarter-2026-financial

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.